{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T16:38:34Z","timestamp":1755794314101},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,4]]},"DOI":"10.7759\/cureus.17709","type":"journal-article","created":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T12:01:15Z","timestamp":1630756875000},"source":"Crossref","is-referenced-by-count":2,"title":["Is Prophylaxis the Only Way Out for Cytokine Release Syndrome Associated With Chimeric Antigen T-cell Therapy?"],"prefix":"10.7759","author":[{"given":"Prashil","family":"Dave","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Pallares Vela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Cancarevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2591","article-title":"CAR T-cell therapy: full speed ahead","volume":"37 Suppl 1","author":"Sermer D","year":"2019","unstructured":"Sermer D, Brentjens R. CAR T-cell therapy: full speed ahead. Hematol Oncol. 2019, 37 Suppl 1:95-100. 10.1002\/hon.2591","journal-title":"Hematol Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw2127","article-title":"Driving CAR T cell translation forward","volume":"11","author":"Schultz L","year":"2019","unstructured":"Schultz L, Mackall C. Driving CAR T cell translation forward. Sci Transl Med. 2019, 11:eaaw2127. 10.1126\/scitranslmed.aaw2127","journal-title":"Sci Transl Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.it.2015.06.004","article-title":"Engineering CAR-T cells: design concepts","volume":"36","author":"Srivastava S","year":"2015","unstructured":"Srivastava S, Riddell SR. Engineering CAR-T cells: design concepts. Trends in Immunology. 2015, 36:494-502. 10.1016%2Fj.it.2015.06.004","journal-title":"Trends in Immunology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6175","article-title":"Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy","volume":"6","author":"Tang XJ","year":"2015","unstructured":"Tang XJ, Sun XY, Huang KM, et al.. Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy. Oncotarget. 2015, 6:44179-90. 10.18632\/oncotarget.6175","journal-title":"Oncotarget"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0918-x","article-title":"The biological basis and clinical symptoms of CAR-T therapy-associated toxicites","volume":"9","author":"Titov A","year":"2018","unstructured":"Titov A, Petukhov A, Staliarova A, et al.. The biological basis and clinical symptoms of CAR-T therapy-associated toxicites. Cell Death Dis. 2018, 9:897. 10.1038\/s41419-018-0918-x","journal-title":"Cell Death Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","volume":"37 Suppl 1","author":"Neelapu SS","year":"2019","unstructured":"Neelapu SS. Managing the toxicities of CAR T-cell therapy. Hematol Oncol. 2019, 37 Suppl 1:48-52. 10.1002\/hon.2595","journal-title":"Hematol Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1378\/chest.117.4.1162","article-title":"Anti-inflammatory cytokines","volume":"117","author":"Opal SM","year":"2000","unstructured":"Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest. 2000, 117:1162-72. 10.1378\/chest.117.4.1162","journal-title":"Chest"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1091581815584918","article-title":"Cytokines: the good, the bad, and the deadly","volume":"34","author":"Ramani T","year":"2015","unstructured":"Ramani T, Auletta CS, Weinstock D, Mounho-Zamora B, Ryan PC, Salcedo TW, Bannish G. Cytokines: the good, the bad, and the deadly. Int J Toxicol. 2015, 34:355-65. 10.1177\/1091581815584918","journal-title":"Int J Toxicol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20030407","article-title":"Principles of interleukin (IL)-6-type cytokine signalling and its regulation","volume":"374","author":"Heinrich PC","year":"2003","unstructured":"Heinrich PC, Behrmann I, Haan S, Hermanns HM, M\u00fcller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003, 374:1-20. 10.1042\/BJ20030407","journal-title":"Biochem J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.15406\/moji.2016.04.00121","article-title":"Cytokines and their role in health and disease: a brief overview","volume":"4","author":"Gulati K","year":"2016","unstructured":"Gulati K, Guhathakurta S, Joshi J, et al.. Cytokines and their role in health and disease: a brief overview. Medcrave Online Journal of Immunology. 2016, 4:00121. 10.15406\/moji.2016.04.00121","journal-title":"Medcrave Online Journal of Immunology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel","volume":"11","author":"Porter D","year":"2018","unstructured":"Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018, 11:35. 10.1186\/s13045-018-0571-y","journal-title":"J Hematol Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S202015","article-title":"Cytokine release syndrome: current perspectives","volume":"8","author":"Murthy H","year":"2019","unstructured":"Murthy H, Iqbal M, Chavez JC, Kharfan-Dabaja MA. Cytokine release syndrome: current perspectives. Immunotargets Ther. 2019, 8:43-52. 10.2147\/ITT.S202015","journal-title":"Immunotargets Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000004087","article-title":"Critical care management of toxicities associated with targeted agents and immunotherapies for cancer","volume":"48","author":"Gutierrez C","year":"2020","unstructured":"Gutierrez C, McEvoy C, Munshi L, Stephens RS, Detsky ME, Nates JL, Pastores SM. Critical care management of toxicities associated with targeted agents and immunotherapies for cancer. Crit Care Med. 2020, 48:10-21. 10.1097\/CCM.0000000000004087","journal-title":"Crit Care Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S150524","article-title":"Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy","volume":"15","author":"Riegler LL","year":"2019","unstructured":"Riegler LL, Jones GP, Lee DW. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Ther Clin Risk Manag. 2019, 15:323-35. 10.2147\/TCRM.S150524","journal-title":"Ther Clin Risk Manag"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee DW","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, et al.. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019, 25:625-38. 10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-Cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase i anti-CD22 CAR T-cell trial","volume":"38","author":"Shah NN","year":"2020","unstructured":"Shah NN, Highfill SL, Shalabi H, et al.. CD4\/CD8 T-Cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase i anti-CD22 CAR T-cell trial. J Clin Oncol. 2020, 38:1938-50. 10.1200\/JCO.19.03279","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran KJ","year":"2019","unstructured":"Curran KJ, Margossian SP, Kernan NA, et al.. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL. Blood. 2019, 134:2361-8. 10.1182\/blood.2019001641","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje N","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, et al.. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019, 380:1726-37. 10.1056\/NEJMoa1817226","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang M","year":"2020","unstructured":"Wang M, Munoz J, Goy A, et al.. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020, 382:1331-42. 10.1056\/NEJMoa1914347","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos CA","year":"2020","unstructured":"Ramos CA, Grover NS, Beaven AW, et al.. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2020, 38:3794-804. 10.1200\/JCO.20.01342","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large b-cell lymphoma","volume":"377","author":"Neelapu SS","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al.. Axicabtagene ciloleucel CAR T-cell therapy in refractory large b-cell lymphoma. N Engl J Med. 2017, 377:2531-44. 10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2019.01.005","article-title":"Risks and benefits of chimeric antigen receptor T-Cell (CAR-T) therapy in cancer: a systematic review and meta-analysis","volume":"33","author":"Grigor EJ","year":"2019","unstructured":"Grigor EJ, Fergusson D, Kekre N, et al.. Risks and benefits of chimeric antigen receptor T-Cell (CAR-T) therapy in cancer: a systematic review and meta-analysis. Transfus Med Rev. 2019, 33:98-110. 10.1016\/j.tmrv.2019.01.005","journal-title":"Transfus Med Rev"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster SJ","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al.. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019, 380:45-56. 10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu SS","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, et al.. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018, 15:47-62. 10.1038\/nrclinonc.2017.148","journal-title":"Nat Rev Clin Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee DW","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, et al.. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014, 124:188-95. 10.1182\/blood-2014-05-552729","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle CJ","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, et al.. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016, 8:355ra116. 10.1126\/scitranslmed.aaf8621","journal-title":"Sci Transl Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0280-y","article-title":"Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia","volume":"10","author":"Liu S","year":"2020","unstructured":"Liu S, Deng B, Yin Z, et al.. Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer J. 2020, 10:15. 10.1038\/s41408-020-0280-y","journal-title":"Blood Cancer J"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey DT","year":"2016","unstructured":"Teachey DT, Lacey SF, Shaw PA, et al.. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016, 6:664-79. 10.1158\/2159-8290.CD-16-0040","journal-title":"Cancer Discov"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial","volume":"39","author":"Kadauke S","year":"2021","unstructured":"Kadauke S, Myers RM, Li Y, et al.. Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial. J Clin Oncol. 2021, 39:920-30. 10.1200\/JCO.20.02477","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila ML","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, et al.. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014, 6:224ra25. 10.1126\/scitranslmed.3008226","journal-title":"Sci Transl Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke FL","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, et al.. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019, 20:31-42. 10.1016\/S1470-2045(18)30864-7","journal-title":"Lancet Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le RQ","year":"2018","unstructured":"Le RQ, Li L, Yuan W, et al.. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018, 23:943-7. 10.1634\/theoncologist.2018-0028","journal-title":"Oncologist"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-021-00209-2","article-title":"Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy","volume":"10","author":"Zhang L","year":"2021","unstructured":"Zhang L, Wang S, Xu J, et al.. Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy. Exp Hematol Oncol. 2021, 10:16. 10.1186\/s40164-021-00209-2","journal-title":"Exp Hematol Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/68981-is-prophylaxis-the-only-way-out-for-cytokine-release-syndrome-associated-with-chimeric-antigen-t-cell-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:30:37Z","timestamp":1707507037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/68981-is-prophylaxis-the-only-way-out-for-cytokine-release-syndrome-associated-with-chimeric-antigen-t-cell-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,4]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.17709","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,4]]}}}